Damage to mitochondria (mt) is a major side effect of highly active antiretroviral therapy (HAART) that includes a nucleoside reverse transcriptase inhibitor (NRTI). Such damage is associated with the onset of lipodystrophy in HAART-treated HIV+ patients. To further investigate mt changes during this syndrome, we analysed the expression of mtRNA in adipocytes from lipodystrophic HIV+ patients taking NRTI-containing HAART and compared it with similar cells from healthy individuals.
Materials and methods
Total RNA was extracted from adipocytes collected from different anatomical locations of 11 HIV+ lipodystrophic patients and seven healthy control individuals. RNA was reverse transcribed and Taqman-based real-time PCR was used to quantify three different mt transcripts (ND1, CYTB and ND6 gene products). mtRNA content was normalized versus the housekeeping transcript L13.
Results
ND1, CYTB and ND6 expression was significantly reduced in HIV+ lipodystrophic patients. HIV+ men and women did not differ in a statistically significant way regarding the levels of ND1 and ND6, whereas the opposite occurred for CYTB.
Conclusions
Lipodystrophy following treatment with NRTI-containing HAART is associated with a decrease in adipose tissue mtRNAs.
References
1.
CarrA., SamarasK., BurtonS., LawM., FreundJ., ChisholmD.J., & CooperD.A.A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.AIDS1998; 12: F51–F58.
BrinkmanK., SmeitinkJ.A., RomijnJ.A., & ReissP.Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophyLancet1999; 354: 1112–1115.
4.
CarrA., SamarasK., ThorisdottirA., KaufmannG.R., ChisholmD.J., & CooperD.A.Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study.Lancet1999; 353: 2093–2099.
5.
CarrA., MillerJ., LawM., & CooperD.A.A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.AIDS2000; 14: F25–F32.
6.
CôtéH.C., BrummeZ.L., CraibK.J., AlexanderC.S., WynhovenB., TingL., WongH., HarrisM., HarriganP.R., O'ShaughnessyM.V., & MontanerJ.S.Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients.New England Journal of Medicine2002; 346: 811–820.
7.
CossarizzaA., TroianoL., & MussiniC.Mitochondria and HIV infection: the first decade.Journal of Biological Regulators & Homeostatic Agents2002; 16: 18–24.
8.
CossarizzaA., PintiM., MorettiL., BricalliD., BianchiR., TroianoL., FernandezM.G., BalliF., BrambillaP., MussiniC., & ViganòA.Mitochondrial functionality and mitochondrial DNA content in lymphocytes of vertically infected human immunodeficiency virus-positive children with highly active antiretroviral therapy-related lipodystrophyJournal of Infectious Diseases2002; 185: 299–305.
9.
CossarizzaA., RivaA., PintiM., AmmannatoS., FedeliP., MussiniC., EspositoR., & GalliM.Increased mitochondrial DNA content in peripheral blood lymphocytes from HIV-infected patients with lipodystrophy.Antiviral Therapy2003; 8: 315–321.
10.
HoyJ.F., GahanM.E., CarrA., SmithD., LewinS.R., WesselinghS., & CooperD.A.Changes in mitochondrial DNA in peripheral blood mononuclear cells from HIV-infected patients with lipoatrophy randomized to receive abacavir.Journal of Infectious Diseases2004; 190: 688–692.
11.
ShikumaC.M., HuN., MilneC., YostF., WaslienC., ShimizuS., & ShiramizuB.Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy.AIDS2001; 15: 1801–1809.
12.
ShiramizuB., ShikumaK.M., KamemotoL., GerschensonM., ErdemG., PintiM., CossarizzaA., & ShikumaC.Placenta and cord blood mitochondrial DNA toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy.Journal of Acquired Immune Deficiency Syndromes2003; 32: 370–374.
13.
CossarizzaA., & MoyleG.Antiretroviral nucleoside and nucleotide analogues and mitochondria.AIDS2004; 18: 137–151.
14.
GalluzziL., PintiM., TroianoL., PradaN., NasiM., FerraresiR., SalomoniP., MussiniC., & CossarizzaA.Changes in mitochondrial RNA production in cells treated with nucleoside analogues.Antiviral Therapy2005; 10: 191–195.
15.
AndersonS., BankierA.T., BarrellB.G., de BruijnM.H., CoulsonA.R., DrouinJ., EperonI.C., NierlichD.P., RoeB.A., SangerF., SchreierP.H., SmithA.J., StadenR., & YoungI.G.Sequence and organization of the human mitochondrial genome.Nature1981; 290: 457–465.
16.
BonenL.The mitochondrial genome: so simple yet so complex.Current Opinion in Genetics & Development1991; 1: 515–522.
17.
ShueyD.J., & AttardiG.Characterization of an RNA polymerase activity from HeLa cell mitochondria, which initiates transcription at the heavy strand rRNA promoter and the light strand promoter in human mitochondrial DNA.Journal of Biological Chemistry1985; 260: 1952–1958.
18.
ClaytonD.A.Transcription of the mammalian mitochondrial genome.Annual Reviews of Biochemistry1984; 53: 573–594.
19.
ClaytonD.A.Transcription and replication of mitochondrial DNA.Human Reproduction2000; 15 (Suppl 2): 11–17.
20.
SambrookJ., & RussellD.W.Molecular Cloning: a Laboratory Manual.3rd edn 2001. New York: Cold Spring Harbor Laboratory Press.
21.
PintiM., TroianoL., NasiM., MonterastelliE., MorettiL., BellodiC., MazzacaniA., MussiC., SalvioliG., & CossarizzaA.Development of real time PCR assays for the quantification of Fas and FasL mRNA levels in lymphocytes: studies on centenarians.Mechanisms of Ageing & Development2003; 124: 511–516.
22.
FuX., MenkeJ.G., ChenY., ZhouG., MacNaulK.L., WrightS.D., SparrowC.P., & LundE.G.27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells.Journal of Biological Chemistry2001; 276: 38378–38387.
23.
CherryC.L., GahanM.E., McArthurJ.C., LewinS.R., HoyJ.F., & WesselinghS.L.Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat.Journal of Acquired Immune Deficiency Syndromes2002; 30: 271–277.
24.
WalkerU.A., BickelM., Lutke VolksbeckS.I., KetelsenU.P., SchoferH., SetzerB., VenhoffN., RickertsV., & StaszewskiS.Evidence of nucleoside analogue reverse transcriptase inhibitor - associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients.Journal of Acquired Immune Deficiency Syndromes2002; 29: 117–121.
25.
NolanD., HammondE., MartinA., TaylorL., HerrmannS., McKinnonE., MetcalfC., LathamB., & MallalS.Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy.AIDS2003; 17: 1329–1338.
26.
van der ValkM., CasulaM., WeverlingzG.J., van KuijkK., van Eck-SmitB., HulseboschH.J., NieuwkerkP., van EedenA., BrinkmanK., LangeJ., de RondeA., & ReissP.Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy.Antiviral Therapy2004; 9: 385–393.
27.
MallalS.A., JohnM., MooreC.B., JamesI.R., & McKinnonE.J.Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection.AIDS2000; 14: 309–1316.
PaceC.S., MartinA.M., HammondE.L., MamotteC.D., NolanD.A., & MallalS.A.Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients.Antiviral Therapy2003; 8: 323–331.
30.
CarrA., WorkmanC., SmithD.E., HoyJ., HudsonJ., DoongN., MartinA., AminJ., FreundJ., LawM., & CooperD.A.; for the Mitochondrial Toxicity (MITOX) Study Group. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial.Journal of the American Medical Association2002; 288: 207–215.
31.
MartinA., SmithD.E., CarrA., RinglandC., AminJ., EmeryS., HoyJ., WorkmanC., DoongN., FreundJ., & CooperD.A.; for the Mitochondrial Toxicity (MITOX) Study Group. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study.AIDS2004; 18: 1029–1036.
32.
McComseyG.A., PaulsenD.M., LonerganJ.T., HessenthalerS.M., HoppelC.L., WilliamsV.C., FisherR.L., CherryC.L., White-OwenC., ThompsonK.A., RossS.T., HernandezJ.E., & RossL.L.Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine.AIDS2005; 19: 15–24.
33.
NegredoE., ParedesR., PeraireJ., PedrolE., CôtéH., GelS., FumozC.R., RuizL., AbrilV., Rodriguez de CastroE., OchoaC., Martinez-PicadoJ., MontanerJ., Rey-JolyC., & ClotetB. (Swatch Study Team). Alternation of antiretroviral drug regimens for HIV infection. Efficacy, safety and tolerability at week 96 of the Swatch Study.Antiviral Therapy2004; 9: 889–893.
34.
HammondE., NolanD., JamesI., MetcalfC., & MallalS.Reduction of mitochondrial DNA content and respiratory chain activity occurs in adipocytes within 6-12 months of commencing nucleoside reverse transcriptase inhibitor therapy.AIDS2004; 18: 815–817.
35.
Seidel-RogolB.L., & ShadelG.S.Modulation of mitochondrial transcription in response to mtDNA depletion and repletion in HeLa cells.Nucleic Acids Research2002; 30: 1929–1934.
36.
MiròO., LopezS., Rodriguez de la ConcepcionM., MartinezE., PedrolE., GarrabouG., GiraltM., CardellachF., GatellJ.M., VilarroyaF., & CasademontJ.Upregulatory mechanisms compensate for mitochondrial DNA depletion in asymptomatic individuals receiving stavudine plus didanosine.Journal of Acquired Immune Deficiency Syndromes2004; 37: 1550–1555.
37.
d'AmatiG., & LewisW.Zidovudine causes early increases in mitochondrial ribonucleic acid abundance and induces ultrastructural changes in cultured mouse muscle cells.Laboratory Investigations1994; 71: 879–884.
38.
MallonP., UnemoriP., BowenM., MillerJ., WinterbothamM., KelleherA., WilliamsK., CooperD., & CarrA.Nucleoside reverse transcriptase inhibitors decrease mitochondrial and PPARgamma gene expression in adipose tissue after only 2 weeks in HIV-uninfected healthy adults.11th Conference on Retroviruses & Opportunistic Infections. 11–14 February 2004, San Francisco, CA, USA. Abstract 76.
39.
SuomalainenA., MajanderA., PihkoH., PeltonenL., & SyvanenA.C.Quantification of tRNA3243(Leu) point mutation of mitochondrial DNA in MELAS patients and its effects on mitochondrial transcription.Human Molecular Genetics1993; 2: 525–534.
40.
Bonod-BidaudC., GiraudS., MandonG., MoussonB., & StepienG.Quantification of OXPHOS gene transcripts during muscle cell differentiation in patients with mitochondrial myopathies.Experimental Cell Research1999; 246: 91–97.
